Neutralization of mitogenic lectins by intravenous immunoglobulin (IVIg) prevents T cell activation: Does IVIg really have a direct effect on T cells?

Clinical and Experimental Immunology

Volumn 166, Issue 3, 2011, Pages 352-360

  Padet, L ^a,b   St Amour, I ^a   Aubin, E ^a,b   Bazin, R ^a,b  

^a HÉMA QUÉBEC   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Glycan; IVIg; Lectin; Phytohaemagglutinin; T cell activation

Indexed keywords

HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN G; LECTIN;

ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; MITOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIGEN PRESENTATION; CELL LINE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; JURKAT CELLS; LECTINS; LYMPHOCYTE ACTIVATION; MITOGENS; PHYTOHEMAGGLUTININS; T-LYMPHOCYTES;

EID: 80855151611     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04476.x     Document Type: Article

References (36)

1. Imbach P, Barandun S, d'Apuzzo V etal. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1:1228-31.
2. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26:513-33.
3. Arnson Y, Shoenfeld Y, Amital H. Intravenous immunoglobulin therapy for autoimmune diseases. Autoimmunity 2009; 42:553-60.
4. Hughes RA, Dalakas MC, Cornblath DR, Latov N, Weksler ME, Relkin N. Clinical applications of intravenous immunoglobulins in neurology. Clin Exp Immunol 2009; 158 (Suppl 1):34-42.
5. Lemieux R, Bazin R, Neron S. Therapeutic intravenous immunoglobulins. Mol Immunol 2005; 42:839-48.
6. Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol 2011; 127:315-23.
7. Abbas AK, Lohr J, Knoechel B, Nagabhushanam V. T cell tolerance and autoimmunity. Autoimmun Rev 2004; 3:471-5.
8. Crane IJ, Forrester JV. Th1 and Th2 lymphocytes in autoimmune disease. Crit Rev Immunol 2005; 25:75-102.
9. King C, Tangye SG, Mackay CR. T follicular helper (TFH) cells in normal and dysregulated immune responses. Annu Rev Immunol 2008; 26:741-66.
10. Tsubakio T, Kurata Y, Katagiri S etal. Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose gamma-globulin therapy in patients with idiopathic thrombocytopenic purpura. Clin Exp Immunol 1983; 53:697-702.
11. Dammacco F, Iodice G, Campobasso N. Treatment of adult patients with idiopathic thrombocytopenic purpura with intravenous immunoglobulin: effects on circulating T cell subsets and PWM-induced antibody synthesis in vitro. Br J Haematol 1986; 62:125-35.
12. Mouzaki A, Theodoropoulou M, Gianakopoulos I, Vlaha V, Kyrtsonis MC, Maniatis A. Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: their role in prognosis. Blood 2002; 100:1774-9.
13. Aktas O, Zipp F. Regulation of self-reactive T cells by human immunoglobulins - implications for multiple sclerosis therapy. Curr Pharm Des 2003; 9:245-56.
14. Yamada H, Morikawa M, Furuta I etal. Intravenous immunoglobulin treatment in women with recurrent abortions: increased cytokine levels and reduced Th1/Th2 lymphocyte ratio in peripheral blood. Am J Reprod Immunol 2003; 49:84-9.
15. Achiron A, Margalit R, Hershkoviz R etal. Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion. J Clin Invest 1994; 93:600-5.
16. Skansen-Saphir U, Andersson J, Bjork L etal. Down-regulation of lymphokine synthesis by intravenous gammaglobulin is dependent upon accessory cells. Scand J Immunol 1998; 47:229-35.
17. Aubin E, Lemieux R, Bazin R. Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation. Blood 2010; 115:1727-34.
18. Bazin R, Lemieux R, Tremblay T, St-Amour I. Tetramolecular immune complexes are more efficient than IVIg to prevent antibody-dependent in vitro and in vivo phagocytosis of blood cells. Br J Haematol 2004; 127:90-6.
19. Rosenstreich DL, Farrar JJ, Dougherty S. Absolute macrophage dependency of T lymphocyte activation by mitogens. J Immunol 1976; 116:131-9.
20. Habu S, Raff MC. Accessory cell dependence of lectin-induced proliferation of mouse T lymphocytes. Eur J Immunol 1977; 7:451-7.
21. de Vries JE, Caviles AP, Jr, Bont WS, Mendelsohn J. The role of monocytes in human lymphocyte activation by mitogens. J Immunol 1979; 122:1099-107.
22. Stohl W. Modulation of the immune response by immunoglobulin for intravenous use. I. Inhibition of pokeweed mitogen-induced B cell differentiation. Clin Exp Immunol 1985; 62:200-7.
23. Kondo N, Ozawa T, Mushiake K etal. Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin. J Clin Immunol 1991; 11:152-8.
24. Klaesson S, Ringden O, Markling L, Remberger M, Lundkvist I. Immune modulatory effects of immunoglobulins on cell-mediated immune responses in vitro. Scand J Immunol 1993; 38:477-84.
25. Toyoda M, Zhang X, Petrosian A, Galera OA, Wang SJ, Jordan SC. Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin. J Clin Immunol 1994; 14:178-89.
26. Tha-In T, Metselaar HJ, Tilanus HW etal. Superior immunomodulatory effects of intravenous immunoglobulins on human T-cells and dendritic cells: comparison to calcineurin inhibitors. Transplantation 2006; 81:1725-34.
27. Heidt S, Roelen DL, Eijsink C, Eikmans M, Claas FH, Mulder A. Intravenous immunoglobulin preparations have no direct effect on B cell proliferation and immunoglobulin production. Clin Exp Immunol 2009; 158:99-105.
28. MacMillan HF, Lee T, Issekutz AC. Intravenous immunoglobulin G-mediated inhibition of T-cell proliferation reflects an endogenous mechanism by which IgG modulates T-cell activation. Clin Immunol 2009; 132:222-33.
29. Tawfik DS, Cowan KR, Walsh AM, Hamilton WS, Goldman FD. Exogenous immunoglobulin downregulates T-cell receptor signaling and cytokine production. Pediatr Allergy Immunol 2011; DOI: 10.1111/j.1399-3038.2010.01129.x.
30. Neron S, Boire G, Dussault N etal. CD40-activated B cells from patients with systemic lupus erythematosus can be modulated by therapeutic immunoglobulins in vitro. Arch Immunol Ther Exp (Warsz) 2009; 57:447-58.
31. Lamoureux J, Aubin E, Lemieux R. Autoantibodies purified from therapeutic preparations of intravenous immunoglobulins (IVIg) induce the formation of autoimmune complexes in normal human serum: a role in the in vivo mechanisms of action of IVIg? Int Immunol 2004; 16:929-36.
32. Jefferis R, Lund J, Mizutani H etal. A comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins. Biochem J 1990; 268:529-37.
33. Jefferis R. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog 2005; 21:11-16.
34. Holland M, Yagi H, Takahashi N etal. Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis. Biochim Biophys Acta 2006; 1760:669-77.
35. Green ED, Baenziger JU. Oligosaccharide specificities of Phaseolus vulgaris leukoagglutinating and erythroagglutinating phytohemagglutinins. Interactions with N-glycanase-released oligosaccharides. J Biol Chem 1987; 262:12018-29.
36. Malaise MG, Franchimont P, Bouillene C, Houssier C, Mahieu PR. Increased concanavalin A-binding capacity of immunoglobulin G purified from sera of patients with rheumatoid arthritis. Clin Exp Immunol 1987; 68:543-51.